Royalty Pharma plc (RPRX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in New York City, NY, United States. The current CEO is Pablo Legorreta.
RPRX has IPO date of 2020-06-16, 75 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $20.92B.
Royalty Pharma plc is a biopharmaceutical royalty company that identifies, evaluates, and acquires royalty streams from innovative drug therapies across the United States. The company collaborates with academic institutions, research hospitals, biotechnology companies, and pharmaceutical firms to fund biopharmaceutical innovation. Its diversified portfolio includes royalties on approximately 35 marketed therapies and 10 development-stage product candidates spanning therapeutic areas such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. Founded in 1996 and headquartered in New York, Royalty Pharma generates revenue through its ownership of royalty interests in marketed drugs while supporting the advancement of new treatments.
